<DOC>
	<DOCNO>NCT02616614</DOCNO>
	<brief_summary>Actavis develop generic formulation clindamycin 1.2 % benzoyl peroxide 3.75 % gel . This study design evaluate safety efficacy formulation subject Acne Vulgaris</brief_summary>
	<brief_title>Double-blind Placebo-controlled Trial Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel Acne Vulgaris</brief_title>
	<detailed_description>This randomize , double blind , three-arm , parallel group , placebo control bioequivalence study clinical endpoint , multiple study site , design establish bioequivalence clindamycin 1.2 % benzoyl peroxide 3.75 % gel Actavis Onexton® ( clindamycin 1.2 % benzoyl peroxide 3.75 % ) gel treatment subject Acne Vulgaris . The primary objective evaluate bioequivalence generic clindamycin 1.2 % benzoyl peroxide 3.75 % gel Onexton® treatment subject acne vulgaris .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Benzoyl Peroxide</mesh_term>
	<criteria>Healthy male nonpregnant female age ≥ 12 ≤ 40 year clinical diagnosis acne vulgaris On face , ≥25 noninflammatory lesion ( i.e. , open close comedo ) ≥ 20 inflammatory lesion ( i.e. , papule pustule ) ≤ 2 nodulocystic lesion ( i.e. , nodule cyst ) . For purpose study treatment evaluation , lesion limit facial treatment area . Counts nodules cyst report separately included inflammatory noninflammatory lesion count . Lesions involve eye scalp exclude count . ( Subjects may acne lesion area body ( e.g. , back ) ) . Subjects must Investigator 's Global Assessment ( IGA ) acne severity grade 2 , 3 , 4 . Willing refrain use topical acne medication antibiotic 12 week treatment period . Subjects may use topical acne treatment significant measurable systemic absorption treatment acne back , shoulder chest ( e.g . benzoyl peroxide , salicylic acid ) . Subjects 18 year age old must provide Institutional Review Board ( IRB ) approve write informed consent . Subjects least 12 year age less 18 year age must provide IRB approve write assent ; write assent must accompany IRB approve write informed consent subject 's legally acceptable representative ( i.e. , parent guardian ) . In addition , subject legally acceptable representative ( i.e. , parent guardian ) must sign Health Insurance Portability Accountability Act ( HIPAA ) authorization , applicable . Male subject Female subject childbearing potential must use accepted method birth control must agree practice abstinence , study start 30 day last administration study drug . All female subject consider childbearing potential unless surgically sterilize postmenopausal least 1 year . Any following method birth control acceptable : oral contraceptive , contraceptive patches/implants ( e.g. , Norplant® ) , vaginal ring ( NuvaRing® ) , DepoProvera® ( Medroxy progesterone acetate ) , double barrier method ( e.g. , condom spermicide ) intrauterine device ( IUD ) . Female subject child bear potential must negative urine pregnancy test baseline . Subjects use makeup must use brands/types makeup minimum period 14 day prior study entry must agree change makeup brand/type frequency use throughout study . History hypersensitivity allergy clindamycin benzoyl peroxide and/or study medication ingredient lincomycin allow product use study . Presence skin condition would interfere diagnosis assessment acne vulgaris ( e.g. , face : rosacea , dermatitis , psoriasis , squamous cell carcinoma , eczema , acneform eruption cause medication , steroid acne , steroid folliculitis , bacterial folliculitis ) . Excessive facial hair ( beard , sideburn , moustache , etc . ) would interfere diagnosis assessment acne vulgaris . Patient allow shave excessive facial hair least day visit site study assessment . Use within 6 month prior baseline oral retinoids ( e.g . Accutane® ) therapeutic vitamin A supplement great 10,000 units/day . Use le 3 month prior baseline estrogen oral contraceptive ; use therapy must remain constant throughout study . Use face within 1 month prior baseline study : 1 ) cryodestruction , 2 ) dermabrasion , 3 ) photodynamic therapy , 4 ) acne surgery , 5 ) intralesional steroid , 6 ) xray therapy . Use within 1 month prior baseline : 1 ) spironolactone , 2 ) systemic steroid , 3 ) systemic antibiotic , 4 ) systemic treatment acne vulgaris 5 ) systemic antiinflammatory agent . Use within 2 week prior baseline : 1 ) topical steroid , 2 ) topical retinoids , 3 ) topical acne treatment include overthecounter preparation , 4 ) topical anti inflammatory agent , 5 ) medicate cleanser 6 ) topical antibiotic . Subjects acne fulminans , secondary acne ( e.g. , chloracne drug induce acne ) exclude participation . Female subject pregnant , nurse plan become pregnant study participation ( Visit 1 Visit 4 30 day post visit 4 ) exclude study participation . Subjects receive radiation therapy and/or antineoplastic agent within 90 day prior baseline exclude study participation . Subjects unstable medical disorder clinically significant lifethreatening disease exclude study participation . Subjects ongoing malignancy require systemic treatment exclude study participation . In addition , subject malignancy skin facial area exclude study participation . Subjects engage activity involve excessive prolonged exposure sunlight weather extreme , wind cold , exclude study participation . Subjects facial sunburn exclude study participation Subjects consume excessive amount alcohol ( great two drink per day ) use drug abuse ( include , limited , cannabinoids cocaine ) judge medical history exclude study participation . History presence significant smoking ( 10 cigarette form tobacco smoking/day consumption tobacco product ) . Systolic blood pressure le 90 mm Hg 140 mm Hg , Diastolic blood pressure le 60 mm Hg 90 mm Hg Pulse rate le 50 beats/minute 100 beats/minute . Subjects participate investigational drug study ( i.e. , subject treat investigational drug ) within 1 month prior baseline exclude study participation . Subjects participate non treatment study observational study registry study consider inclusion . Major illness , per investigator 's discretion , 3 month screen . Subjects previously enrol study exclude study participation . Subjects laser therapy electrodesiccation facial area within 180 day prior study entry exclude participation . Subjects cosmetic procedure ( e.g. , facial ) may affect efficacy safety profile investigational product within 14 day prior study entry exclude participation . Subjects general anesthesia reason subject receive neuromuscular block agent within 14 day prior study entry exclude study participation . Subjects baseline score 3 ( severe , marked/intense ) per Application Site Reaction Scale ( Section 5.2 ) exclude participation . Any employee staff research site exclude study participation .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>